ArticleJournal of clinical hypertension (Greenwich, Conn.)2010
Isradipine for treatment of acute hypertension in hospitalized children and adolescents.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Exploiting meta-analysis of genome-wide interaction with serum 25-hydroxyvitamin D to identify novel genetic loci associated with pulmonary function.The American journal of clinical nutrition · 2024Pooled it
- Review
- Treatment of Hypertension in Children.Current hypertension reviews · 2024Review
- Management of Hypertensive Crises in Children: A Review of the Recent Literature.Frontiers in pediatrics · 2022Review
- Antihypertensive agents: a long way to safe drug prescribing in children.Pediatric nephrology (Berlin, Germany) · 2020Review
- Epidemiology and Management of Children with Hypertensive Crisis: A Single-Center Experience.Journal of pediatric intensive care · 2020Article
- A Practical Guide to the Management of Severe Hypertension in Children.Paediatric drugs · 2020Article
- Hypertensive Crisis in Pediatric Patients: An Overview.Frontiers in pediatrics · 2020Review
- Hypertensive crisis in children and adolescents.Pediatric nephrology (Berlin, Germany) · 2019Review
- Evaluation and management of elevated blood pressures in hospitalized children.Pediatric nephrology (Berlin, Germany) · 2019Review
- Neonatal hypertension: cases, causes, and clinical approach.Pediatric nephrology (Berlin, Germany) · 2019Review
- Evaluation and treatment of hypertensive crises in children.Integrated blood pressure control · 2016Review
- Pediatric hypertensive emergencies.Current hypertension reports · 2014Review
- The efficacy and safety of intravenous hydralazine for the treatment of hypertension in the hospitalized child.Pediatric nephrology (Berlin, Germany) · 2014Article
- Therapy of acute hypertension in hospitalized children and adolescents.Current hypertension reports · 2014Review
- Management of blood pressure in children.Current opinion in nephrology and hypertension · 2012Review
- Hypertensive crisis in children.Pediatric nephrology (Berlin, Germany) · 2012Review
- Hypertension in infancy: diagnosis, management and outcome.Pediatric nephrology (Berlin, Germany) · 2012Review
- Drug treatment of hypertensive crisis in children.Paediatric drugs · 2011Review
- Short- and long-term physiologic and pharmacologic control of blood pressure in pediatric patients.Integrated blood pressure control · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Severe acute hypertension in pediatric patients requires prompt and controlled blood pressure (BP) reduction to prevent end-organ damage. The authors aimed to examine the efficacy and safety of isradipine, an orally administered second-generation dihydropyridine calcium channel blocker, for treatment of acute hypertension in hospitalized pediatric patients. A retrospective analysis of 391 doses of isradipine administered to 282 patients (58% boys) with acute hypertension and median age of 12.8 years (range, 0.1-21.9) was performed. Primary diagnoses included renal disease (n=154), malignancy (45), nonrenal transplant (37), neurologic disease (21), and other (25). The decrease in systolic BP was 16.3%±11.6% (mean ± SD) and diastolic BP was 24.2%±17.2%. BPs were significantly lower in all age groups and in all diagnosis categories following isradipine administration. The decrease in BP was the highest in children younger than 2 years. The mean increase in pulse after a dose was 7±17 beats per minute. Forty adverse events were reported in 33 patients, with emesis and nausea being the most common; 5 of these events were hypotension. The authors conclude that isradipine effectively reduces BP in a wide variety of hospitalized children and adolescents with acute hypertension. A lower initial dose of 0.05 mg/kg may be appropriate in children younger than 2 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.